Skip to main content

Question for Department of Health and Social Care

UIN HL603, tabled on 26 May 2021

To ask Her Majesty's Government what assessment they have made of the benefits of protecting funding to Clinical Commissioning Groups for diabetes technology.

Answered on

7 June 2021

No assessment has been made on the benefits of protecting funding to Clinical Commissioning Groups for diabetes technology. Clinical Commissioning Groups are responsible for commissioning diabetes services for their local populations and are best placed as clinically-led organisations that have both the local knowledge and accountability, to make commissioning decisions in the best interests of their patients. This includes prescribing technologies for people living with diabetes, for example glucose monitoring devices.

Commissioning decisions for the adoption of technology products in diabetes are always guided by clinical and cost effective assessments, delivered by NICE and other regulatory bodies.